On Health Policy Archives

Letter to Principal Deputy Commissioner Sharfstein Expressing Concerns About the Food and Drug Administration Amendments Act (FDAAA)

October 6, 2009. In September 2007, the Food and Drug Administration Amendments Act (FDAAA) was signed into law.

NCHR Comment on “Statement of Policy: Testing of Component Parts With Respect to Section 108 of the Consumer Product Safety Improvement Act”

September 16, 2009. Given that phthalate concentrations can be diluted in large toys, we agree with Commission staff that testing phthalate content as a percentage of the entire toy or child care article is less effective than testing materials and component parts that may contain phthalates.

NCHR Comment to the FDA on “Medical Devices: Ophthalmic Devices; Laser-Assisted In Situ Keratomileusis (LASIK) Devices; Establishing a Docket”

September 14, 2009. The National Research Center for Women & Families submits the following comments regarding the laser-assisted in situ keratomileusis (LASIK) and the post market experience associated with the use of LASIK devices.

NCHR Testimony to the FDA on Transparency

June 24, 2009. I have scrutinized FDA policies, processes, and decisions as a Congressional investigator and in my current position.

NCHR Letter to U.S. Senator Charles Grassley (Ranking Member of the Finance Committee) supporting S. 301, the “Physician Payments Sunshine Act of 2009”

May 29, 2009. The Physician Payments Sunshine Act would bring much needed transparency to the often secretive financial relationships between medical products manufacturers and health care professionals.